NCT07016750Phase 3Recruiting

A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa

Study sponsor: Krystal Biotech, Inc. · KRYS

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-12Estimated
Enrollment · participants16Estimated
Source updated2026-03-12Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Planned enrollment decreased by 4 participants

Before: 20 participants (planned). After: 16 participants (planned).

Check registry source

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: To evaluate the safety and tolerability of KB803. Measure: To evaluate the effect of ophthalmic KB803 versus placebo on frequency of corneal. abrasion symptoms.. After: Measure: To evaluate the safety and tolerability of KB803. Measure: To evaluate the effect of ophthalmic KB803 on frequency of corneal abrasion symptoms..

Planned enrollment increased by 4 participants

Before: 16 participants (planned). After: 20 participants (planned).

Primary completion date changed

Before: Mar 2026. After: Dec 2026.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview